Omicron BA.2

Early data from a phase 2/3 trial suggest that the new Pfizer and BioNTech omicron booster increases protective antibodies against the BA.5 subvariant in adults 7 days after administration.

Rates of severe disease and ICU admissions do not significantly differ among patients with COVID-19 receiving either bebtelovimab or Paxlovid, according to a recent study.

Last week, Anthony S. Fauci, MD, announced that he will step down as director of the National Institute of Allergy and Infectious Diseases in December.

The omicron variant of the SARS-CoV-2 virus presents unique challenges for patients with immunodeficiencies and their health care providers, according to a paper published in The Journal of Allergy and Clinical Immunology: In Practice.

In the United States, the omicron subvariant BA.2 accounted for 35% of SARS-CoV-2 infections in the week ending March 19, according to the CDC.

CDC data show that the omicron BA.2 subvariant of SARS-CoV-2 accounted for approximately 35% of COVID-19 cases in the United States during the week ending March 19, up from around 22% the week before.